Drugs / ALVAC-HIV gp160MN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000813 | ? → Jun 1995 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC-HIV gp160MN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000813 ↗ |
| Known as | vCP125 | “ALVAC-HIV gp160MN (vCP125)” NCT00000813 ↗ |
| Modality | Vaccine | “ALVAC vCP125 HIV-1 gp160 MN live canarypox recombinant vaccine” NCT00000813 ↗ |
| Route | Intramuscular | “intramuscular injections of ALVAC gp160 MN” NCT00000813 ↗ |